FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of January 2013
Commission File Number: 001-15152
SYNGENTA AG
(Translation of registrant’s name into English)
Schwarzwaldallee 215
4058 Basel
Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|
Form 20-F
|
X
|
Form 40-F
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
|
Yes
|
No
|
X
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|
Yes
|
No
|
X
|
Indicate by check mark whether by furnishing the information contained in this Form, the Registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
|
Yes
|
No
|
X
|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A
Re: SYNGENTA AG
|
Disclosure:
|
“Management announcement”
|
Herewith we furnish a press release related to Syngenta AG. The full text of the press release is the following:
# # #
|
Syngenta International AG
|
Analyst/Investor contact: | ||||
| Media Office | Jennifer Gough | ||||
|
CH-4002 Basel
|
Paul Barrett | Switzerland | +41 61 323 5059 | ||
|
Switzerland
|
Switzerland | +41 61 323 2323 | USA | +1 202 737 6521 | |
| Tel: | +41 61 323 2323 | ||||
| Fax: | +41 61 323 2424 | Daniel Braxton | Lars Oestergaard | ||
| Switzerland | +41 61 323 2323 | Switzerland | +41 61 323 6793 | ||
|
www.syngenta.com
|
USA | +1 202 737 6520 | |||
Basel, Switzerland, January 28, 2013
Management announcement
It is with great regret that Syngenta today reports the death of Dr. Alejandro Aruffo, who took medical leave as Head of R&D in October.
Mike Mack, Chief Executive Officer, said: “Sandro was a brilliant and dedicated man. He played a pivotal role in strengthening Syngenta’s R&D function and in delivering our strategy. He will be greatly missed by his colleagues at Syngenta and our thoughts go out to his family.”
Robert Berendes, Head of Business Development, will continue ad interim leadership of the R&D function.
Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.
|
Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions.Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements.We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties.Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.
|
Syngenta – January 28, 2013 / Page 1 of 1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
SYNGENTA AG
|
||||||
|
Date:
|
January 28, 2013
|
By:
|
/s/ Tobias Meili | |||
|
Name:
|
Dr. Tobias Meili
|
|||||
|
Title:
|
Head Corporate Legal Affairs
|
|||||
|
By:
|
/s/ Brigitte Benz
|
|||||
|
Name:
|
Brigitte Benz
|
|||||
|
Title:
|
Head Shareholder Services &
Group Administration
|
|||||